Article
Tracking of Glycans Structure and Metallomics Profiles in BRAF Mutated Melanoma Cells Treated with Vemurafenib.
International journal of molecular sciences - 4 Jan 2021
Nisiewicz Monika K, Kowalczyk Agata, Sobiepanek Anna, Jagielska Agata, Wagner Barbara, Nowakowska Julita, Gniadek Marianna, Grudzinski Ireneusz P, Kobiela Tomasz, Nowicka Anna M
Abstract excerpt
Nearly half of patients with advanced and metastatic melanomas harbor a BRAF mutation. Vemurafenib (VEM), a BRAF inhibitor, is used to treat such patients, however, responses to VEM are very short-lived due to intrinsic, adaptive and/or acquired resistance. In this context, we present the action of the B-Raf serine-threonine protein kinase inhibitor (vemurafenib) on the glycans structure and metallomics profiles...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.